BR0013650A - Composições injetáveis de micropartìculas de buprenorfina e seu uso - Google Patents
Composições injetáveis de micropartìculas de buprenorfina e seu usoInfo
- Publication number
- BR0013650A BR0013650A BR0013650-6A BR0013650A BR0013650A BR 0013650 A BR0013650 A BR 0013650A BR 0013650 A BR0013650 A BR 0013650A BR 0013650 A BR0013650 A BR 0013650A
- Authority
- BR
- Brazil
- Prior art keywords
- opioid
- partial
- agonist
- injectable compositions
- opioid antagonist
- Prior art date
Links
- 239000007972 injectable composition Substances 0.000 title abstract 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title abstract 2
- 229960001736 buprenorphine Drugs 0.000 title abstract 2
- 239000011859 microparticle Substances 0.000 title 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 3
- 239000003401 opiate antagonist Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003402 opiate agonist Substances 0.000 abstract 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 abstract 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 abstract 1
- 229960002069 diamorphine Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 229960001797 methadone Drugs 0.000 abstract 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 1
- 229960003086 naltrexone Drugs 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15111299P | 1999-08-27 | 1999-08-27 | |
| PCT/US2000/023390 WO2001015699A1 (en) | 1999-08-27 | 2000-08-25 | Injectable buprenorphine microparticle compositions and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0013650A true BR0013650A (pt) | 2002-05-07 |
Family
ID=22537367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0013650-6A BR0013650A (pt) | 1999-08-27 | 2000-08-25 | Composições injetáveis de micropartìculas de buprenorfina e seu uso |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6495155B1 (enExample) |
| EP (1) | EP1212061B1 (enExample) |
| JP (1) | JP4913298B2 (enExample) |
| KR (1) | KR100730440B1 (enExample) |
| CN (2) | CN1248689C (enExample) |
| AT (1) | ATE280579T1 (enExample) |
| AU (1) | AU765496C (enExample) |
| BR (1) | BR0013650A (enExample) |
| CA (1) | CA2382577C (enExample) |
| CY (1) | CY1106043T1 (enExample) |
| CZ (1) | CZ2002728A3 (enExample) |
| DE (1) | DE60015370T2 (enExample) |
| EA (1) | EA009080B1 (enExample) |
| ES (1) | ES2230154T3 (enExample) |
| HK (1) | HK1046858B (enExample) |
| HU (1) | HUP0203613A3 (enExample) |
| IL (2) | IL148343A0 (enExample) |
| MX (1) | MXPA02002105A (enExample) |
| NO (2) | NO322650B1 (enExample) |
| NZ (1) | NZ517997A (enExample) |
| PL (1) | PL198334B1 (enExample) |
| PT (1) | PT1212061E (enExample) |
| RO (1) | RO121631B1 (enExample) |
| WO (1) | WO2001015699A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1212061E (pt) * | 1999-08-27 | 2005-01-31 | Southern Res Inst | Composicoes injectaveis de microparticulas de buprenorfina e suas utilizacoes |
| US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| US20030003113A1 (en) * | 2001-06-29 | 2003-01-02 | Lewandowski Leon J. | Individualized addiction cessation therapy |
| JP4490095B2 (ja) * | 2001-06-29 | 2010-06-23 | メドグラフト マイクロテック インコーポレイテッド | 生体分解性の注入可能な移植物およびそれに関連する製造方法ならびに使用方法 |
| PL208484B1 (pl) | 2001-07-06 | 2011-05-31 | Penwest Pharmaceuticals Company | Sposoby wytwarzania preparatów oksymorfonu o przedłużonym uwalnianiu |
| CN1551770A (zh) | 2001-07-06 | 2004-12-01 | ������ҩ������˾ | 羟吗啡酮控释制剂 |
| US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
| WO2003026743A2 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
| US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| US7131997B2 (en) | 2002-03-29 | 2006-11-07 | Scimed Life Systems, Inc. | Tissue treatment |
| US7094369B2 (en) | 2002-03-29 | 2006-08-22 | Scimed Life Systems, Inc. | Processes for manufacturing polymeric microspheres |
| US7053134B2 (en) | 2002-04-04 | 2006-05-30 | Scimed Life Systems, Inc. | Forming a chemically cross-linked particle of a desired shape and diameter |
| NZ536965A (en) | 2002-05-31 | 2007-02-23 | Titan Pharmaceuticals Inc | Nonerodible polymeric matrix with buprenorphine encapsulated for the treatment of opiate addiction and pain |
| US7041320B1 (en) * | 2002-05-31 | 2006-05-09 | Biotek, Inc. | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence |
| US7842377B2 (en) * | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US7449236B2 (en) | 2002-08-09 | 2008-11-11 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
| US7588825B2 (en) | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
| WO2004078178A1 (en) * | 2003-03-03 | 2004-09-16 | Markus Heilig | Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use |
| MXPA05010450A (es) | 2003-03-31 | 2005-11-04 | Titan Pharmaceuticals Inc | Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina. |
| US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
| US7901770B2 (en) | 2003-11-04 | 2011-03-08 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
| US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
| US7919499B2 (en) * | 2004-04-22 | 2011-04-05 | Alkermes, Inc. | Naltrexone long acting formulations and methods of use |
| FR2869801B1 (fr) * | 2004-05-05 | 2008-09-12 | Ethypharm Sa | Procede de preparation de compositions a liberation prolongee et utilisation de ces compositions pour le traitement des affections chroniques du systeme nerveux central (snc) |
| US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| EP1789076B1 (en) | 2004-08-04 | 2016-01-20 | Clinuvel Pharmaceuticals Limited | Methods of inducing melanogenesis in a subject. |
| US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
| US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
| US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
| US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
| US20070141160A1 (en) * | 2005-12-15 | 2007-06-21 | Brown Laura J | Method of treatment for osteoarthritis by local intra-articular injection of microparticles |
| US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US7501179B2 (en) | 2005-12-21 | 2009-03-10 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| WO2008106571A2 (en) * | 2007-02-28 | 2008-09-04 | Abbott Laboratories | Sustained release parenteral formulations of buprenorphine |
| MX2010002409A (es) | 2007-09-03 | 2010-05-19 | Nanotherapeutics Inc | Composiciones y metodos para la distribucion de farmacos escasamente solubles. |
| JP5502751B2 (ja) * | 2007-12-20 | 2014-05-28 | エボニック コーポレイション | 低残留溶媒濃度を有する微粒子を調製するためのプロセス |
| CN104984343B (zh) * | 2008-09-24 | 2019-04-02 | 赢创罗姆有限公司 | 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物 |
| MX2011003047A (es) * | 2008-09-24 | 2011-04-14 | Evonik Roehm Gmbh | Composicion farmaceutica de opioide de liberacion controlada ph dependiente con resistencia contra la influencia de etanol. |
| WO2010034344A1 (en) | 2008-09-24 | 2010-04-01 | Evonik Röhm Gmbh | Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol |
| US20100268191A1 (en) * | 2009-04-21 | 2010-10-21 | Medtronic Vascular, Inc. | Drug Delivery Catheter using Frangible Microcapsules and Delivery Method |
| US9125867B2 (en) | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2481017B (en) * | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| WO2013126552A1 (en) | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| NZ631539A (en) | 2012-04-17 | 2016-10-28 | Purdue Pharma Lp | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| CN102836131A (zh) * | 2012-09-28 | 2012-12-26 | 山东大学 | 丁丙诺啡皮下注射用缓释微球制剂及其制备方法 |
| US9636308B2 (en) | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| US9393211B2 (en) * | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| JP6135292B2 (ja) * | 2013-05-10 | 2017-05-31 | ニプロ株式会社 | マイクロカプセル製剤の製造方法 |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| ES2808150T3 (es) | 2014-11-07 | 2021-02-25 | Indivior Uk Ltd | Regímenes de dosificación de buprenorfina |
| MX2018010194A (es) | 2016-02-23 | 2019-06-12 | Biodelivery Sciences Int Inc | Microsferas de buprenorfina de liberacion sostenida (srbm) y metodos de uso de las mismas. |
| FI3512518T3 (fi) | 2016-09-13 | 2023-01-31 | Hitaasti vapautuvia buprenorfiiniformulaatioita | |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| NZ766474A (en) | 2018-05-11 | 2023-03-31 | Alar Pharmaceuticals Inc | Long-acting injectable formulations and crystalline forms of buprenorphine derivatives |
| US20220313686A1 (en) * | 2019-08-12 | 2022-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pharmaceutical compositions comprising a combination of opioid antagonists |
| US20210059943A1 (en) * | 2019-09-04 | 2021-03-04 | Buffalo Pacific LLC | Systems and methods addressing multiple aspects to provide a comprehensive recovery program for addictions, chronic conditions and diseases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US4568559A (en) | 1984-02-06 | 1986-02-04 | Biotek, Inc. | Composite core coated microparticles and process of preparing same |
| US4623588A (en) | 1984-02-06 | 1986-11-18 | Biotek, Inc. | Controlled release composite core coated microparticles |
| GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US5143661A (en) * | 1987-05-26 | 1992-09-01 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules |
| FR2618674B1 (fr) | 1987-07-30 | 1990-06-15 | Ire Celltarg Sa | Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation |
| GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
| US4902515A (en) * | 1988-04-28 | 1990-02-20 | E. I. Dupont De Nemours And Company | Polylactide compositions |
| US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| WO1990013361A1 (en) | 1989-05-04 | 1990-11-15 | Southern Research Institute | Improved encapsulation process and products therefrom |
| US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
| AU2605592A (en) * | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US5633000A (en) | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
| US5716631A (en) | 1995-09-29 | 1998-02-10 | Rdn Therapeutics Inc. | Long acting narcotic analgesics and antagonists |
| US5919473A (en) * | 1997-05-12 | 1999-07-06 | Elkhoury; George F. | Methods and devices for delivering opioid analgesics to wounds via a subdermal implant |
| PT1212061E (pt) * | 1999-08-27 | 2005-01-31 | Southern Res Inst | Composicoes injectaveis de microparticulas de buprenorfina e suas utilizacoes |
-
2000
- 2000-08-25 PT PT00959422T patent/PT1212061E/pt unknown
- 2000-08-25 WO PCT/US2000/023390 patent/WO2001015699A1/en not_active Ceased
- 2000-08-25 IL IL14834300A patent/IL148343A0/xx active IP Right Grant
- 2000-08-25 EP EP20000959422 patent/EP1212061B1/en not_active Expired - Lifetime
- 2000-08-25 CN CNB008147280A patent/CN1248689C/zh not_active Expired - Fee Related
- 2000-08-25 CZ CZ2002728A patent/CZ2002728A3/cs unknown
- 2000-08-25 BR BR0013650-6A patent/BR0013650A/pt not_active Application Discontinuation
- 2000-08-25 CA CA002382577A patent/CA2382577C/en not_active Expired - Lifetime
- 2000-08-25 MX MXPA02002105A patent/MXPA02002105A/es active IP Right Grant
- 2000-08-25 AT AT00959422T patent/ATE280579T1/de not_active IP Right Cessation
- 2000-08-25 PL PL354977A patent/PL198334B1/pl not_active IP Right Cessation
- 2000-08-25 EA EA200200295A patent/EA009080B1/ru not_active IP Right Cessation
- 2000-08-25 ES ES00959422T patent/ES2230154T3/es not_active Expired - Lifetime
- 2000-08-25 JP JP2001519913A patent/JP4913298B2/ja not_active Expired - Lifetime
- 2000-08-25 HK HK02108436.3A patent/HK1046858B/en not_active IP Right Cessation
- 2000-08-25 KR KR1020027002567A patent/KR100730440B1/ko not_active Expired - Fee Related
- 2000-08-25 RO ROA200200190A patent/RO121631B1/ro unknown
- 2000-08-25 DE DE60015370T patent/DE60015370T2/de not_active Expired - Lifetime
- 2000-08-25 AU AU70751/00A patent/AU765496C/en not_active Ceased
- 2000-08-25 US US09/648,255 patent/US6495155B1/en not_active Expired - Lifetime
- 2000-08-25 NZ NZ517997A patent/NZ517997A/xx unknown
- 2000-08-25 CN CNB2005100927174A patent/CN100387228C/zh not_active Expired - Fee Related
- 2000-08-25 HU HU0203613A patent/HUP0203613A3/hu unknown
-
2002
- 2002-02-24 IL IL148343A patent/IL148343A/en not_active IP Right Cessation
- 2002-02-26 NO NO20020924A patent/NO322650B1/no not_active IP Right Cessation
- 2002-12-17 US US10/324,062 patent/US7473431B2/en not_active Expired - Lifetime
-
2005
- 2005-01-14 CY CY20051100081T patent/CY1106043T1/el unknown
-
2006
- 2006-07-12 NO NO20063239A patent/NO20063239L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0013650A (pt) | Composições injetáveis de micropartìculas de buprenorfina e seu uso | |
| US6525062B2 (en) | Method of treating pain using nalbuphine and opioid antagonists | |
| Carroll et al. | Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist | |
| US20040180916A1 (en) | Treatment of pain with combinations of nalbuphine and other kappa-opioid receptor agonists and opioid receptor antagonists | |
| WO2001085257A3 (en) | Opioid antagonist compositions and dosage forms | |
| BRPI0511224A (pt) | método para preparar uma composição contendo antagonistas de opióides, produto contendo antagonistas de opióides, composição contendo antagonistas de opióides, formulação de dosagem injetável, kit, método para prevenir ou tratar um efeito colateral associado com um opióide num paciente, e para tratar ou impedir dor num paciente | |
| BR0109150A (pt) | Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente | |
| KR910002444A (ko) | 스피로사이클릭 피페리딘 유도체, 이의 제조방법, 이의 용도 및 이를 함유하는 약학 조성물 | |
| JP2003514013A (ja) | 医薬組成物 | |
| BRPI0413693A (pt) | composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero | |
| WO2002070524A3 (en) | N-but-3-enyl norbuprenorphine and its use as analgesic | |
| WO2001001972A3 (en) | SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | |
| Kamerling et al. | Narcotic analgesics, their detection and pain measurement in the horse: a review | |
| JP2000513704A (ja) | 麻薬禁断症候群に対する抗ミネラロコルチコイド化合物の新規な用途 | |
| EA200100871A1 (ru) | Кристаллическая форма эплеренона, обладающая повышенной скоростью растворения | |
| JP2004529959A (ja) | 鎮痛剤組成物と手法 | |
| Sribanditmongkol et al. | Inhibition of morphine tolerance and dependence by diazepam and its relation to the CNS Met-enkephalin levels | |
| ATE287265T1 (de) | Verwendung von schwachen opioiden und gemischten opioidagonisten / -antagonisten zur therapie der harninkontinenz | |
| BRPI0413607A (pt) | composição farmacêutica para a prevenção e tratamento do vìcio em mamìferos | |
| BRPI0413608A (pt) | composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìfero | |
| AU9266698A (en) | Acidic addition salts of morphine alkaloids and the application thereof | |
| EP1555023A3 (en) | Injectable buprenorphine microparticle compositions and their use | |
| David et al. | Antagonism of bremazocine‐induced urination as a test for kappa‐opioid receptor antagonists within the phenylpiperidine series | |
| Kamei et al. | Antinociceptive effect of lipopolysaccharide from Pantoea agglomerans on streptozotocin-induced diabetic mice | |
| AU2006298393B2 (en) | Use of neboglamine in the treatment of toxicodependency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: BROOKWOOD PHARMACEUTICALS, INC. (US) Free format text: TRANSFERIDO DE: SOUTHERN RESEARCH INSTITUTE |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |